Skip to main content
Erschienen in: Tumor Biology 12/2015

01.12.2015 | Research Article

Quercetin 3-O-glucoside suppresses epidermal growth factor–induced migration by inhibiting EGFR signaling in pancreatic cancer cells

verfasst von: Jungwhoi Lee, Song-I Han, Jeong-Hun Yun, Jae Hoon Kim

Erschienen in: Tumor Biology | Ausgabe 12/2015

Einloggen, um Zugang zu erhalten

Abstract

Pancreatic cancer is one of the most dangerous cancers and is associated with a grave prognosis. Despite increased knowledge of the complex signaling networks responsible for progression of pancreatic cancer, many challenging therapies have fallen short of expectations. In this study, we examined the anti-migratory effect of quercetin 3-O-glucoside in epidermal growth factor–induced cell migration by inhibiting EGF receptor (EGFR) signaling in several human pancreatic cancer cell lines. Treatment with quercetin, quercetin 3-O-glucoside, and quercetin 7-O-glucoside differentially suppressed epidermal growth factor–induced migration activity of human pancreatic cancer cells. In particular, quercetin 3-O-glucoside strongly inhibited the infiltration activity of pancreatic cancer cells in a dose-dependent manner. Furthermore, quercetin 3-O-glucoside exerted the anti-migratory effect even at a relatively low dose compared with other forms of quercetin. The anti-tumor effects of quercetin 3-O-glucoside were mediated by selectively inhibiting the EGFR-mediated FAK, AKT, MEK1/2, and ERK1/2 signaling pathway. Combinatorial treatment with quercetin 3-O-glucoside plus gemcitabine showed the synergistic anti-migratory effect on epidermal growth factor–induced cell migration in human pancreatic cancer cell lines. These results suggest that quercetin 3-O-glucoside has potential for anti-metastatic therapy in human pancreatic cancer.
Literatur
1.
Zurück zum Zitat Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA: Cancer J Clin. 2014;64:9–29. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA: Cancer J Clin. 2014;64:9–29.
2.
Zurück zum Zitat Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol. 2010;7:163–72.CrossRefPubMed Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol. 2010;7:163–72.CrossRefPubMed
3.
Zurück zum Zitat Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nat Rev Cancer. 2002;2:897–909.CrossRefPubMed Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nat Rev Cancer. 2002;2:897–909.CrossRefPubMed
4.
Zurück zum Zitat Cano CE, Motoo Y, Iovanna JL. Epithelial-to-mesenchymal transition in pancreatic adenocarcinoma. Sci World J. 2010;10:1947–57.CrossRef Cano CE, Motoo Y, Iovanna JL. Epithelial-to-mesenchymal transition in pancreatic adenocarcinoma. Sci World J. 2010;10:1947–57.CrossRef
5.
Zurück zum Zitat Inoue S, Tezel E, Nakao A. Molecular diagnosis of pancreatic cancer. Hepato-Gastroenterology. 2001;48:933–8.PubMed Inoue S, Tezel E, Nakao A. Molecular diagnosis of pancreatic cancer. Hepato-Gastroenterology. 2001;48:933–8.PubMed
6.
Zurück zum Zitat Formica JV, Regelson W. Review of the biology of quercetin and related bioflavonoids. Food Chem Toxicol : Int J Published British Ind Biol Res Assoc. 1995;33:1061–80.CrossRef Formica JV, Regelson W. Review of the biology of quercetin and related bioflavonoids. Food Chem Toxicol : Int J Published British Ind Biol Res Assoc. 1995;33:1061–80.CrossRef
7.
Zurück zum Zitat Surh YJ. Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer. 2003;3:768–80.CrossRefPubMed Surh YJ. Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer. 2003;3:768–80.CrossRefPubMed
8.
Zurück zum Zitat Russo M, Spagnuolo C, Tedesco I, Bilotto S, Russo GL. The flavonoid quercetin in disease prevention and therapy: facts and fancies. Biochem Pharmacol. 2012;83:6–15.CrossRefPubMed Russo M, Spagnuolo C, Tedesco I, Bilotto S, Russo GL. The flavonoid quercetin in disease prevention and therapy: facts and fancies. Biochem Pharmacol. 2012;83:6–15.CrossRefPubMed
9.
Zurück zum Zitat Romagnolo DF, Selmin OI. Flavonoids and cancer prevention: a review of the evidence. J Nutr Gerontol Geriatr. 2012;31:206–38.CrossRefPubMed Romagnolo DF, Selmin OI. Flavonoids and cancer prevention: a review of the evidence. J Nutr Gerontol Geriatr. 2012;31:206–38.CrossRefPubMed
10.
Zurück zum Zitat Yang JH, Hsia TC, Kuo HM, Chao PD, Chou CC, Wei YH, et al. Inhibition of lung cancer cell growth by quercetin glucuronides via g2/m arrest and induction of apoptosis. Drug Metab Disposition: Biol Fate Chem. 2006;34:296–304.CrossRef Yang JH, Hsia TC, Kuo HM, Chao PD, Chou CC, Wei YH, et al. Inhibition of lung cancer cell growth by quercetin glucuronides via g2/m arrest and induction of apoptosis. Drug Metab Disposition: Biol Fate Chem. 2006;34:296–304.CrossRef
11.
Zurück zum Zitat Gibellini L, Pinti M, Nasi M, Montagna JP, De Biasi S, Roat E, et al. Quercetin and cancer chemoprevention. Evid Based Complement Alternat Med: eCAM. 2011;2011:591356.CrossRefPubMedPubMedCentral Gibellini L, Pinti M, Nasi M, Montagna JP, De Biasi S, Roat E, et al. Quercetin and cancer chemoprevention. Evid Based Complement Alternat Med: eCAM. 2011;2011:591356.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Murakami A, Ashida H, Terao J. Multitargeted cancer prevention by quercetin. Cancer Lett. 2008;269:315–25.CrossRefPubMed Murakami A, Ashida H, Terao J. Multitargeted cancer prevention by quercetin. Cancer Lett. 2008;269:315–25.CrossRefPubMed
13.
Zurück zum Zitat Razavi SM, Zahri S, Zarrini G, Nazemiyeh H, Mohammadi S. Biological activity of quercetin-3-o-glucoside, a known plant flavonoid. Bioorg Khim. 2009;35:414–6.PubMed Razavi SM, Zahri S, Zarrini G, Nazemiyeh H, Mohammadi S. Biological activity of quercetin-3-o-glucoside, a known plant flavonoid. Bioorg Khim. 2009;35:414–6.PubMed
14.
Zurück zum Zitat Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol. 2006;33:369–85.CrossRefPubMed Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol. 2006;33:369–85.CrossRefPubMed
16.
Zurück zum Zitat Lee J, Lee J, Yu H, Choi K, Choi C. Differential dependency of human cancer cells on vascular endothelial growth factor-mediated autocrine growth and survival. Cancer Lett. 2011;309:145–50.CrossRefPubMed Lee J, Lee J, Yu H, Choi K, Choi C. Differential dependency of human cancer cells on vascular endothelial growth factor-mediated autocrine growth and survival. Cancer Lett. 2011;309:145–50.CrossRefPubMed
17.
Zurück zum Zitat Lee J, Ku T, Yu H, Chong K, Ryu SW, Choi K, et al. Blockade of vegf-a suppresses tumor growth via inhibition of autocrine signaling through fak and akt. Cancer Lett. 2012;318:221–5.CrossRefPubMed Lee J, Ku T, Yu H, Chong K, Ryu SW, Choi K, et al. Blockade of vegf-a suppresses tumor growth via inhibition of autocrine signaling through fak and akt. Cancer Lett. 2012;318:221–5.CrossRefPubMed
18.
Zurück zum Zitat Korc M, Chandrasekar B, Yamanaka Y, Friess H, Buchier M, Beger HG. Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. J Clin Investig. 1992;90:1352–60.CrossRefPubMedPubMedCentral Korc M, Chandrasekar B, Yamanaka Y, Friess H, Buchier M, Beger HG. Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. J Clin Investig. 1992;90:1352–60.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Pryczynicz A, Guzinska-Ustymowicz K, Kemona A, Czyzewska J. Expression of egf and egfr strongly correlates with metastasis of pancreatic ductal carcinoma. Anticancer Res. 2008;28:1399–404.PubMed Pryczynicz A, Guzinska-Ustymowicz K, Kemona A, Czyzewska J. Expression of egf and egfr strongly correlates with metastasis of pancreatic ductal carcinoma. Anticancer Res. 2008;28:1399–404.PubMed
20.
Zurück zum Zitat Angst E, Park JL, Moro A, Lu QY, Lu X, Li G, et al. The flavonoid quercetin inhibits pancreatic cancer growth in vitro and in vivo. Pancreas. 2013;42:223–9.CrossRefPubMedPubMedCentral Angst E, Park JL, Moro A, Lu QY, Lu X, Li G, et al. The flavonoid quercetin inhibits pancreatic cancer growth in vitro and in vivo. Pancreas. 2013;42:223–9.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Zhou W, Kallifatidis G, Baumann B, Rausch V, Mattern J, Gladkich J, et al. Dietary polyphenol quercetin targets pancreatic cancer stem cells. Int J Oncol. 2010;37:551–61.PubMed Zhou W, Kallifatidis G, Baumann B, Rausch V, Mattern J, Gladkich J, et al. Dietary polyphenol quercetin targets pancreatic cancer stem cells. Int J Oncol. 2010;37:551–61.PubMed
22.
Zurück zum Zitat Lee LT, Huang YT, Hwang JJ, Lee PP, Ke FC, Nair MP, et al. Blockade of the epidermal growth factor receptor tyrosine kinase activity by quercetin and luteolin leads to growth inhibition and apoptosis of pancreatic tumor cells. Anticancer Res. 2002;22:1615–27.PubMed Lee LT, Huang YT, Hwang JJ, Lee PP, Ke FC, Nair MP, et al. Blockade of the epidermal growth factor receptor tyrosine kinase activity by quercetin and luteolin leads to growth inhibition and apoptosis of pancreatic tumor cells. Anticancer Res. 2002;22:1615–27.PubMed
23.
Zurück zum Zitat Morand C, Manach C, Crespy V, Remesy C. Quercetin 3-o-beta-glucoside is better absorbed than other quercetin forms and is not present in rat plasma. Free Radic Res. 2000;33:667–76.CrossRefPubMed Morand C, Manach C, Crespy V, Remesy C. Quercetin 3-o-beta-glucoside is better absorbed than other quercetin forms and is not present in rat plasma. Free Radic Res. 2000;33:667–76.CrossRefPubMed
24.
Zurück zum Zitat Du XY, Huang J, Xu LQ, Tang DF, Wu L, Zhang LX, et al. The proto-oncogene c-src is involved in primordial follicle activation through the pi3k, pkc and mapk signaling pathways. Reprod Biol Endocrinol : RB&E. 2012;10:58.CrossRef Du XY, Huang J, Xu LQ, Tang DF, Wu L, Zhang LX, et al. The proto-oncogene c-src is involved in primordial follicle activation through the pi3k, pkc and mapk signaling pathways. Reprod Biol Endocrinol : RB&E. 2012;10:58.CrossRef
25.
Zurück zum Zitat Roby KF, Son DS, Taylor CC, Montgomery-Rice V, Kirchoff J, Tang S, et al. Alterations in reproductive function in src tyrosine kinase knockout mice. Endocrine. 2005;26:169–76.CrossRefPubMed Roby KF, Son DS, Taylor CC, Montgomery-Rice V, Kirchoff J, Tang S, et al. Alterations in reproductive function in src tyrosine kinase knockout mice. Endocrine. 2005;26:169–76.CrossRefPubMed
26.
Zurück zum Zitat Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase iii trial of the national cancer institute of canada clinical trials group. J Clin Oncol : Off J Am Soc Clin Oncol. 2007;25:1960–6.CrossRef Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase iii trial of the national cancer institute of canada clinical trials group. J Clin Oncol : Off J Am Soc Clin Oncol. 2007;25:1960–6.CrossRef
27.
Zurück zum Zitat Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. Folfirinox versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.CrossRefPubMed Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. Folfirinox versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.CrossRefPubMed
28.
Zurück zum Zitat Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–703.CrossRef Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–703.CrossRef
29.
Zurück zum Zitat Aranda E, Manzano JL, Rivera F, Galan M, Valladares-Ayerbes M, Pericay C, et al. Phase ii open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (pantar study). Ann Oncol : Off J Europ Soc Med Oncol/ESMO. 2012;23:1919–25.CrossRef Aranda E, Manzano JL, Rivera F, Galan M, Valladares-Ayerbes M, Pericay C, et al. Phase ii open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (pantar study). Ann Oncol : Off J Europ Soc Med Oncol/ESMO. 2012;23:1919–25.CrossRef
Metadaten
Titel
Quercetin 3-O-glucoside suppresses epidermal growth factor–induced migration by inhibiting EGFR signaling in pancreatic cancer cells
verfasst von
Jungwhoi Lee
Song-I Han
Jeong-Hun Yun
Jae Hoon Kim
Publikationsdatum
01.12.2015
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 12/2015
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3682-x

Weitere Artikel der Ausgabe 12/2015

Tumor Biology 12/2015 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.